This 1997 landmark meta-analysis pooled individual patient data from 14 RCTs to determine whether adjuvant doxorubicin-based chemotherapy benefits adults with localized resectable soft-tissue sarcoma. Prior individual trials were too small to answer this question definitively. The analysis assessed local recurrence, distant recurrence, recurrence-free survival, and overall survival at a median follow-up of 9.4 years.
Before this meta-analysis, oncologists were operating on 14 underpowered individual trials — none conclusive, each too small to detect moderate treatment effects in a rare tumor. This paper pooled 98% of all known eligible randomized patients and provided the field's first reliable estimate of effect size.
When you see a patient with localized, resectable, high-grade extremity soft-tissue sarcoma, adjuvant doxorubicin-based chemotherapy is supported by the best available evidence: a 30% reduction in metastasis risk and a statistically significant survival benefit specifically in this group. For non-extremity sites, the recurrence data still favor chemotherapy, but the survival benefit is less clear and must be weighed against doxorubicin toxicity — cardiotoxicity, leucopenia, and treatment noncompliance are real concerns.
The take-home for boards and clinic: chemotherapy significantly delays recurrence in soft-tissue sarcoma, but overall survival benefit remains modest and statistically marginal except in extremity tumors.
This 1997 landmark meta-analysis pooled individual patient data from 14 RCTs to determine whether adjuvant doxorubicin-based chemotherapy benefits adults with localized resectable soft-tissue sarcoma. Prior individual trials were too small to answer this question definitively. The analysis assessed local recurrence, distant recurrence, recurrence-free survival, and overall survival at a median follow-up of 9.4 years.
Before this meta-analysis, oncologists were operating on 14 underpowered individual trials — none conclusive, each too small to detect moderate treatment effects in a rare tumor. This paper pooled 98% of all known eligible randomized patients and provided the field's first reliable estimate of effect size.
When you see a patient with localized, resectable, high-grade extremity soft-tissue sarcoma, adjuvant doxorubicin-based chemotherapy is supported by the best available evidence: a 30% reduction in metastasis risk and a statistically significant survival benefit specifically in this group. For non-extremity sites, the recurrence data still favor chemotherapy, but the survival benefit is less clear and must be weighed against doxorubicin toxicity — cardiotoxicity, leucopenia, and treatment noncompliance are real concerns.
The take-home for boards and clinic: chemotherapy significantly delays recurrence in soft-tissue sarcoma, but overall survival benefit remains modest and statistically marginal except in extremity tumors.